Copy Link Print Information

Dabrafenib Mesylate

(Synonyms: GSK2118436 Mesylate; GSK 2118436B)
84 Cited Publications
Avis client

Based on 84 publication(s) in Google Scholar

Dabrafenib Mesylate is a potent and selective Raf kinase inhibitor with IC50s of 0.6 and 5.0 nM for RafV600E and c-Raf, respectively.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

  • Pureté : 99.94%
  • CAS No.: 1195768-06-9
  • Formule: C24H24F3N5O5S3
  • Masse moléculaire:615.67
  • Stockage:

    4°C, sealed storage, away from moisture

    * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

  • Dabrafenib Mesylate Chemical Structure
    Dabrafenib Mesylate Chemical Structure
  • Experimental Validation Results for Dabrafenib Mesylate
  • Experimental Validation Results for Dabrafenib Mesylate
  • Experimental Validation Results for Dabrafenib Mesylate
  • Experimental Validation Results for Dabrafenib Mesylate
  • Experimental Validation Results for Dabrafenib Mesylate
  • Experimental Validation Results for Dabrafenib Mesylate
  • Experimental Validation Results for Dabrafenib Mesylate
  • Experimental Validation Results for Dabrafenib Mesylate
  • Experimental Validation Results for Dabrafenib Mesylate
  • Experimental Validation Results for Dabrafenib Mesylate
  • Experimental Validation Results for Dabrafenib Mesylate
CAS No.: 1195768-06-9
Size
Prix
Stock
Quantité
Amount: USD 0.00
Please select quantity
or
or

* Veuillez sélectionner la quantité avant d'ajouter des articles.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Dabrafenib Mesylate:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Trouvez votre distributeur local Your local distributor: Hycultec GmbHHycultec
  • Activité biologique
  • Chemical Information
  • Solvant et solubilité
  • Protocole
  • Pureté et documentation
  • Références
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Dabrafenib Mesylate

More
Customer Validation & Images
WBIn Vivo Efficacy StudyCell Proliferation/Viability AssayIFIHC
  • Cell Proliferation/Viability Assay
  • WB
  • In Vivo Efficacy Study
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • IHC
  • In Vivo Efficacy Study
  • IHC
  • WB
  • IF
  • WB

Voir tous les produits spécifiques à Isoform Raf

More

Keywords

MOQ
Minimum order quantity
100 mg

Obtenir un devis En stock

Other size
Obtenir un devis
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Enregistrer
Sign in to MedChemExpress
Enregistrer un nouveau compte

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Dabrafenib Mesylate Chemical Structure
    Dabrafenib Mesylate Chemical Structure
    1/16
  • 1/16

    Dabrafenib Mesylate purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Oct:146:157151. [Abstract]

    Customer Validation
     Dabrafenib (20 μM; 24-48 h). Cell viability is assessed using CCK-8 assays. Dabrafenib (Dab) is used to treat BRAFi-resistant melanoma cells [WM164-DR] for 24 or 48 hours.

  • 1/16

    Dabrafenib Mesylate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Aug;11(29):e2400023. [Abstract]

    Customer Validation
     Inhibitory effects of Dabrafenib (40 µM; 24 h) on TRIM24 phosphorylation and protein interaction between TRIM24 and the DNA-PK complex in NHA/HRasV12/TRIM24 cells. Cells were treated with Dabrafenib for 24 h.

  • 1/16

    Dabrafenib Mesylate purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2024 Mar 19;5(3):101471. [Abstract]

    Customer Validation
     Dabrafenib (30 mg/kg, p.o., 28 days). Relative tumor volumes and mice weights in sequential treatment groups with either vehicle or NEO2734 in A375 subcutaneous-bearing mice. Mice were switched to vehicle or NEO2734 treatment at day 28 (n = 6 for dabrafenib + trametinib to vehicle, n = 5 for dabrafenib + trametinib to NEO2734) (4 mg/kg NEO2734, 5 days/week; 30 mg/kg dabrafenib + 0.6 mg/kg trametinib daily).

  • 1/16

    Dabrafenib Mesylate purchased from MedChemExpress. Usage Cited in: J Am Soc Nephrol. 2024 Jan 1;35(1):22-40. [Abstract]

    Customer Validation
     HK-2 cells were pretreated with different doses of dabrafenib (Dabrafenib Mesylate), starting 1 hour before 5 µM cisplatin treatment for 48 hours, and IC50 of 0.77 µM was determined for the protection of cell viability.

  • 1/16

    Dabrafenib Mesylate purchased from MedChemExpress. Usage Cited in: J Am Soc Nephrol. 2024 Jan 1;35(1):22-40. [Abstract]

    Customer Validation
     Three human cancer cell lines, neuroblastoma Kelly, testicular seminoma JKT-1, and pluripotent embryonal carcinoma cell line NCCIT, were studied. The tumor cell lines were initially pretreated with 3 µM of dabrafenib (Dabrafenib Mesylate), AZD5438, or both drugs for 1 hour and then treated with 10 µM cisplatin and 3 µM AZD5438, dabrafenib, or both drugs and incubated for 48 hours. Cell viability was measured at 48 hours using the CellTiter-Glo (Promega) assay.

  • 1/16

    Dabrafenib Mesylate purchased from MedChemExpress. Usage Cited in: J Am Soc Nephrol. 2024 Jan 1;35(1):22-40. [Abstract]

    Customer Validation
     Experimental protocol of cisplatin injection, saline administration, and dabrafenib (Dabrafenib Mesylate) oral delivery. Renal tissues were stained with H&E and PAS stain and scored by a pathologist blinded to the experimental conditions In all bar graphs, dots represent the number of mice. Renal tissues were stained with H&E and PAS stain and scored by a pathologist blinded to the experimental conditions In all bar graphs, dots represent the number of mice.

  • 1/16

    Dabrafenib Mesylate purchased from MedChemExpress. Usage Cited in: J Am Soc Nephrol. 2024 Jan 1;35(1):22-40. [Abstract]

    Customer Validation
     Mice cotreated with dabrafenib and cisplatin had a reduction in pERK levels compared with cisplatin alone, showing 2.6-fold reduction of pERK with dabrafenib (Dabrafenib Mesylate, 12 mg/kg, oral, three times a day for three consecutive days) cotreatment compared with cisplatin alone treated mice.

  • 1/16

    Dabrafenib Mesylate purchased from MedChemExpress. Usage Cited in: J Am Soc Nephrol. 2024 Jan 1;35(1):22-40. [Abstract]

    Customer Validation
     TUNEL assay performed on mouse kidney sections showed increased cell death in cisplatin alone treated mice (average 0.07±0.007 MFI/cell) on day 3 of treatments and significant protection from cell death (average 0.03±0.008 MFI/cell) with dabrafenib (Dabrafenib Mesylate, 12 mg/kg, oral, three times a day for three consecutive days) cotreatment.

  • 1/16

    Dabrafenib Mesylate purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2020 Mar 16;37(3):387-402.e7. [Abstract]

    Customer Validation
     MCF-7 cells were seeded in 10-11 M E2 to which fulvestrant (F), dabrafenib (D), trametinib (T) or selumetinib (S) were subsequently added at 10-9, 10-6, 10-7 or 10-6 M, respectively. After 6 days, proteins were measured by immunoblotting, and phosphorylation levels (as defined by the levels of the phosphorylated form over total protein) relative to the vehicle-treated cells were set to 1.

  • 1/16

    Dabrafenib Mesylate purchased from MedChemExpress. Usage Cited in: Cell Syst. 2020 Nov 18;11(5):478-494.e9. [Abstract]

    Customer Validation
     Dabrafenib (25 mg/kg; p.o.; 5 days). Immunofluorescence microscopy of pERK in A375 mouse xenografts treated either with vehicle alone or dabrafenib plus trametinib for 5 days.

  • 1/16

    Dabrafenib Mesylate purchased from MedChemExpress. Usage Cited in: Int J Cancer. 2019 Mar 15;144(6):1379-1390. [Abstract]

    Customer Validation
     Western blot confirmed increased MAPK pathway activity in NEC-DUE2 cells when compared to NECDUE1. Treatment with PLX4032 (1 μM), Dabrafenib (100 nM), or GSK1120212 (100 nM) for 4 hours leads to decreased MAPK signaling in NEC-DUE2 cells. Lysates are immunoblotted for the proteins indicated.

  • Dabrafenib Mesylate